Search clinical trials for: Placebo to match Atacicept

Total 1420 results

Vera Therapeutics, Inc.

Recruiting

Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

IgA Nephropathy | Berger Disease

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
EMD Serono

Terminated

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) (ATAMS)

Relapsing Multiple Sclerosis

United States, Sweden, Australia, Czech Republic, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Ukraine, Netherlands, Canada, France, Austria, Lebanon, Switzerland, Belgium
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II) (AUGUST II)

Rheumatoid Arthritis

Germany, United States
EMD Serono

Completed

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (ADDRESS II)

Lupus Erythematosus, Systemic

Korea, Republic of, Philippines, Spain, United States, Czechia, Germany, United Kingdom, South Africa, Poland, Argentina, Italy, Chile, Bulgaria, Japan, Brazil, Mexico, Peru, Russian Federation
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (APRIL-SLE)

Lupus Erythematosus, Systemic

United States, Croatia, Bulgaria, France, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, Malaysia, Latvia, Lithuania, Ukraine, Argentina, Israel, Netherlands, Greece, Taiwan, Philip... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
EMD Serono

Withdrawn

Atacicept Demonstrating Dose RESponSe (ADDRESS)

Systemic Lupus Erythematosus
Merck KGaA, Darmstadt, Germany

Completed

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III) (August III)

Rheumatoid Arthritis

Sweden, France, Netherlands, United Kingdom
Vera Therapeutics, Inc.

Suspended

Atacicept in Subjects With Active Lupus Nephritis (COMPASS) (COMPASS)

Lupus Nephritis (LN)

United States, Puerto Rico, Spain
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

United States, China, Germany, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
HighTide Biopharma Pty Ltd

Completed

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Hypercholesterolemia

Australia
GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Desentum Oy

Completed

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

Birch Pollen Allergy

Canada
Boehringer Ingelheim

Terminated

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Psoriasis

United States, Canada, Germany
Gilead Sciences

Completed

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (TEMPO)

Ventricular Arrhythmia

Netherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (SIGA-246-002)

Healthy

United States
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada
Fujian Akeylink Biotechnology Co., Ltd.

Recruiting

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Desentum Oy

Completed

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy

Finland
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Novaremed Ltd.

Completed

Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients

Diabetic Peripheral Neuropathic Pain

Israel
Galapagos NV
Gilead Sciences

Active, not recruiting

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (FINCH 4)

Rheumatoid Arthritis

Spain, United States, Japan, Korea, Republic of, Taiwan, Belgium, India, Malaysia, Argentina, Australia, Poland, Czechia, Serbia, Germany, New Zealand, Bulgaria, Canada, Chile, France, Hong Kong, Hungary, Ireland, Israel, Italy, Mexico, R... and more
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) (DIVERGENCE 1)

Small Bowel Crohn's Disease

United States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
Kissei Pharmaceutical Co., Ltd.

Completed

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

Endometriosis

United States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine
Kissei Pharmaceutical Co., Ltd.

Terminated

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 5)

Endometriosis

United States, Canada, Puerto Rico
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
ObsEva SA

Terminated

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Endometriosis

United States, Canada, Puerto Rico
Kissei Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Endometriosis

United States, Austria, Bulgaria, Czechia, France, Poland, Romania, Spain, Ukraine, Hungary
Lassen Therapeutics Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Eye Diseases | Endocrine System Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | Proptosis

United States, United Kingdom, Spain
Brii Biosciences Limited

Completed

A Study of BRII-297 in Healthy Adult Subjects

Postpartum Depression

Australia
SecuraBio

Completed

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Asthma

Germany, United Kingdom
Gilead Sciences
Galapagos NV

Completed

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy (FINCH 3)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Korea, Republic of, Japan, Australia, Chile, Russian Federation, Argentina, Germany, New Zealand, Th... and more

Search clinical trials for: Placebo to match Atacicept

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations